Texas is turning to number-crunching in an effort to contain soaring Type 2 diabetes rates. San Antonio will be the first city there to operate a diabetes registry designed to improve both the cost and quality of diabetes care in the state. The Texas state legislature approved the initiative this past spring. The project, which will be administered by the local health department, has been given the extremely imaginative title of Diabetes Registry. (Hey, makes it easy to find in the phone book.) The registry will gather its statistics from labs that perform diabetes blood tests.

The idea behind the project is not new: a similar scheme is already underway in New York City. Makes sense: before you decide how to cope with widespread Type 2 diabetes, you first need to assess exactly what the problems are. Who is missing out on care? Who are most likely to go undiagnosed? What could healthcare providers, teachers, or parents be doing differently?

Officials say that if the registry is successful in San Antonio, the registry may be extended throughout the entire state of Texas. Click here to read more on the community news site My San Antonio.

Yes, that's what it says: curbing the diabetic epidemic with 6 oat waters. CeaProve® is a new test for the early detection of pre-diabetes or impaired glucose tolerance that may help curb the diabetes epidemic. For those of you who have endured a glucose tolerance test - you'll understand the pivotal importance of this new diagnostic test. Ceapro has developed a test that identifies people at risk of type-2 diabetes as early as 5 to 10 years before the disease is diagnosed.

The simple test involves eating 6 oat-wafers and undergoing a finger prick. The test - when repeated at six month intervals - can also show if lifestyle changes are being effective or if more treatment is needed. Ceapro has tested CeaProve in the workplace of several prominent businesses in Edmonton that are interested in helping their employees monitor and preserve their health. Over 90% of tested volunteers were unaware of their risk for diabetes. Of the population studied, 60% were overweight, 56% were over the age of 40, 44 % had a family history of diabetes and over 57% had more than two risk factors for the disease. Although Ceapro is a Canadian-based company, they expect to have Ceaprove available in commercial quantities within the next 45 days. The product will likely be released through regional health initiatives and may also be available through pharmacies and medical laboratories.

Can such a simple test have such a significant impact on the future of one's health? The results tell people, years ahead of time if they are heading down the path to diabetes. With dietary modifications, regular exercise, and an overall improve in lifestyle - wouldn't it be worth it to you?

A study suggests problems with cholesterol regulation in the insulin-producing cells of the pancreas may be responsible for the development of Type 2 diabetes.

A thesis paper written by a graduate student, Dr. Liam Brunham, addressed the fact that a dysfunction in cholesterol regulation is found in beta cells in the pancreas. A thought-provoking connection to this thesis was the fact that beta cells are the cells responsible for producing insulin. A beta cell expert decided to see what would happen if researchers genetically engineered mice without the ABCA1 gene. The ABCA1 gene is the gene responsible for cholesterol regulation in beta cells. Dr. Brunham appears to be the first to identify the role of cholesterol dysfunction resulting in the beta cells inability to properly secrete insulin.

This new research is promising and obviously raises questions in other researcher's minds. One is - what happens when amylin, a hormone produced by the beta cells, builds up to excess amounts? Does this, in fact, impair the beta cells' ability to function properly? Could this be another thesis that trumps Dr. Brunham's hunch for the cause of type 2 diabetes? Some researchers believe that the over-production of amylin and cholesterol may be due to a yet unidentified problem. Of course that is always an option. Science labs across the world could come to a screeching halt if doctor's stopped hypothesizing. As research continues, we will anxiously await the next best thesis paper, courtesy of our promising Graduate Students. Be cool - stay in school!

According to research conducted by Ohio State University, conjugated linoleic acid (CLA) may help reduce body fat, but it also increases your risk for nonalcoholic fatty liver disease.

In 2003, a study showed that a 2 month supplementation of CLA lowered body mass and blood sugars in diabetics. The recent studies conducted on mice fed a CLA supplemented diet lost weight very fast, but also accumulated excessive amounts of fat in their livers - a side effect of rapid weight loss. In addition, excessive accumulation of fat in the liver is associated with insulin resistance, a factor exacerbating type 2 diabetes.

Although the recent findings were conducted on mice, CLA may or may not have a similar effect on humans. CLA has been a hot selling item in supplement stores for years. I wonder what the results would be if people who have taken CLA (the t10c12 variety) for years were to discontinue use for 4 weeks. I would be curious to see the baseline and follow-up tests for body mass, insulin sensitivity and fat accumulation in the liver. Any med students out there interested in setting-up a lab profiling hepatic function in CLA poppers?